Education
About Us
Working with TipRanks
Follow Us
Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
BRNS Stock Chart & Stats
$0.76
>-$0.01(-0.43%)
At close: 4:00 PM EST
$0.76
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$0.56 - $2.92
Previous CloseN/A
Volume10.26K
Average Volume (3M)124.73K
Market Cap
$24.92M
Enterprise Value-$34.27M
Total Cash (Recent Filing)$70.46M
Total Debt (Recent Filing)$11.28M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
May 13, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding40,848,892
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market Cap-1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit37.75
Enterprise Value/Ebitda0.58
Forecast
1Y Price Target
$7.00Price Target Upside821.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.29
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Merger Expands Pipeline And Extends RunwayThe announced all-stock merger with Clywedog creates a larger combined biotech focused on metabolic and autoimmune indications and supplies an estimated cash runway through 2027. This structurally improves funding visibility for upcoming clinical readouts and reduces near-term financing urgency.
Clinical Progress On Prioritized ProgramsConcrete clinical data (encouraging Phase 1 AVALON safety/PD and positive Phase 2 VTP-300 results) reflect execution on a narrowed immunology focus. Sustained clinical progress and multiple planned readouts create durable value drivers and reduce binary risk compared with pure preclinical-stage operations.
Relatively Low Leverage Provides FlexibilityModest debt levels give the company financial flexibility to fund trials, pursue the merger, or raise capital without heavy interest burdens. For a clinical-stage biotech, lower leverage reduces refinancing strain, preserves optionality, and supports strategic decisions over the next several quarters.
Bears Say
Volatile And Absent Recent RevenueRevenue volatility and a drop to zero in 2025 signal a lack of recurring commercial income, leaving the business reliant on financing and milestones. This undermines near- to medium-term cash predictability, increases financing dependency, and limits ability to fund development without dilution or strategic transactions.
Persistent Negative Operating And Free Cash FlowConsistent operating and free cash flow deficits indicate ongoing cash burn tied to R&D and operations. Even with some 2025 improvement, structural negative cash generation elevates dilution and refinancing risk, forcing management to prioritize cash preservation strategies over aggressive development spend.
Nasdaq Minimum Bid Price Noncompliance RiskA formal Nasdaq minimum bid price deficiency introduces a structural listing risk that can lead to reverse splits or delisting if unremedied. Such outcomes can impair liquidity, deter institutional holders, and force management to take governance or capital-structure actions that distract from long-term R&D execution.
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.56 and its highest was $2.92 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $24.92M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is May 13, 2026 which is in 50 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Mar 13, 2026. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.345 by $0.075.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.28.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,848,892 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.345. Following the earnings report the stock price went up 4.833%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
BRNS Stock 12 Month Forecast
Average Price Target
$7.00
▲(821.05% Upside)
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
0.19%
Insiders
0.03% Mutual Funds
18.29% Other Institutional Investors
81.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---